The Canadian Institute's 5th Annual

DRUG PRICING & REIMBURSEMENT IN CANADA

After the Patent Cliff : Pharma Strategies for Overcoming Market Access Hurdles

Tuesday, June 14 to Wednesday, June 15, 2011
Sutton Place Hotel, Toronto, ON

Market access issues are currently among the top issues for pharmaceutical/biopharmaceutical companies in Canada. The hurdles to get to market have increased recently, both from a federal regulatory perspective as well as a provincial reimbursement perspective. Canada is also being impacted by global trends and the implications for the life sciences industry could be significant.

All of these changes are creating uncertainty for all stakeholders – from innovative drug makers to generics, public and private payers, insurance companies, pharmacists and employers.

Highlights include:

  • Implications to Canadian pricing (and PMPRB) as a result of EU price cuts, value based pricing (UK), end of free pricing in Germany
  • Impact of increased transparency and participation by patients and industry in HTA decision making
  • Intergovernmental purchasing issues: What are the provinces doing to coordinate efforts nationally?
  • ‘Value for Money’ – designing, conducting, and reporting economic evaluations – what’s expected of pharma and what can they expect in return?
  • Implications of new generics policies on brand pricing, reimbursement and pharmacy
  • How industry and payers can work together to ensure that the best treatments make it to the right patient at the right time
  • The impact of an aging demographic on pricing and reimbursement

Join us June 14-15 and get the latest updates on where this market presently stands, where it’s headed, and what practical steps you need to take to be more competitive, and compliant, in today’s uncertain and increasingly aggressive market.